Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 May:100 Suppl 3:14-29.
doi: 10.1002/ajh.27592.

Steroid Refractory Acute GVHD: The Hope for a Better Tomorrow

Portia Smallbone  1 , Rohtesh S Mehta  1 , Amin Alousi  1
Affiliations
Review

Steroid Refractory Acute GVHD: The Hope for a Better Tomorrow

Portia Smallbone et al. Am J Hematol. 2025 May.

Abstract

Steroid-refractory acute graft-versus-host disease (SR-AGVHD) presents a significant barrier to successful outcomes following allogeneic hematopoietic cell transplantation (HCT), despite advancements in GVHD prophylaxis and management. While ruxolitinib therapy has shown improved response rates, survival benefits remain elusive. This review explores the definitions and proposed distinct pathophysiology and treatment landscape of SR-AGVHD. Emerging therapies offer potential, yet further research is critical to better define steroid-refractory populations, improve treatment precision with biomarkers, and overcome resistance, particularly in ruxolitinib-refractory cases.

Keywords: graft‐versus‐host disease; hematopoietic stem cell transplantation; immunomodulatory therapies; steroid‐refractory.

PubMed Disclaimer

References

    1. S. Herzog, R. Shanley, S. G. Holtan, M. L. MacMillan, D. J. Weisdorf, and N. E. Jurdi, “Treatment‐Responsive Acute Graft‐Versus‐Host Disease After Post‐Transplantation Cyclophosphamide‐Based Prophylaxis: Incidence and Clinical Outcomes,” Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation and Cellular Therapy 30, no. 7 (2024): 688.e1–688.e9.
    1. H. T. Greinix, D. J. Eikema, L. Koster, et al., “Improved Outcome of Patients With Graft‐Versus‐Host Disease After Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies Over Time: An EBMT Mega‐File Study,” Haematologica 107, no. 5 (2022): 1054–1063.
    1. M. Mielcarek, T. Furlong, B. E. Storer, et al., “Effectiveness and Safety of Lower Dose Prednisone for Initial Treatment of Acute Graft‐Versus‐Host Disease: A Randomized Controlled Trial,” Haematologica 100, no. 6 (2015): 842–848.
    1. P. J. Martin, J. D. Rizzo, J. R. Wingard, et al., “First‐ and Second‐Line Systemic Treatment of Acute Graft‐Versus‐Host Disease: Recommendations of the American Society of Blood and Marrow Transplantation,” Biology of Blood and Marrow Transplantation 18, no. 8 (2012): 1150–1163.
    1. M. L. MacMillan, M. Robin, A. C. Harris, et al., “A Refined Risk Score for Acute Graft‐Versus‐Host Disease That Predicts Response to Initial Therapy, Survival, and Transplant‐Related Mortality,” Biology of Blood and Marrow Transplantation 21, no. 4 (2015): 761–767.

LinkOut - more resources